Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Hepatocellular 3Sarcoma, Ewing 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1

Interventions

Cyclophosphamide 25Rituximab 22fludarabine 14Lenalidomide 10Vincristine 8Doxorubicin 8Prednisone 7Etoposide 7fludarabine phosphate 6Immunotherapy, Adoptive 5polatuzumab vedotin 4Cytarabine 4CT-P10 4Bendamustine Hydrochloride 4Antigens, CD19 4tocilizumab 3Gemcitabine 3Dexamethasone 3Carboplatin 3venetoclax 2veltuzumab 2prednylidene 2ofatumumab 2obinutuzumab 2ixazomib 2ibrutinib 2etoposide phosphate 2deltacortene 2carmustine, poliferprosan 20 drug combination 2acalabrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell × X-Rays × Clear all
NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡